Coya Therapeutics, Common Stock Today
| COYA Stock | 6.68 0.21 3.25% |
PerformanceOK
| Odds Of DistressHigh
|
Coya Therapeutics, is trading at 6.68 as of the 23rd of March 2025, a 3.25 percent up since the beginning of the trading day. The stock's open price was 6.47. Coya Therapeutics, has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of December 2022 | Category Healthcare | Classification Health Care |
Coya Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 16.73 M outstanding shares of which 259.49 K shares are currently shorted by private and institutional investors with about 2.46 trading days to cover. More on Coya Therapeutics, Common
Moving together with Coya Stock
Moving against Coya Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Coya Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Officer | FAPA DO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCoya Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Coya Therapeutics,'s financial leverage. It provides some insight into what part of Coya Therapeutics,'s total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Coya Therapeutics, Common (COYA) is traded on NASDAQ Exchange in USA. It is located in 5850 San Felipe Street, Houston, TX, United States, 77057 and employs 8 people. Coya Therapeutics, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 111.72 M. Coya Therapeutics, Common conducts business under Biotechnology sector and is part of Health Care industry. The entity has 16.73 M outstanding shares of which 259.49 K shares are currently shorted by private and institutional investors with about 2.46 trading days to cover.
Coya Therapeutics, generates negative cash flow from operations
Check Coya Therapeutics, Probability Of Bankruptcy
Ownership AllocationCoya Therapeutics, holds a total of 16.73 Million outstanding shares. Coya Therapeutics, Common shows 7.03 percent of its outstanding shares held by insiders and 26.72 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Coya Ownership Details
Coya Therapeutics, Historical Income Statement
Coya Stock Against Markets
Coya Therapeutics, Corporate Management
| Arun Swaminathan | Chief Officer | Profile | |
| Howard Berman | Executive Chair | Profile | |
| Gregory MacMichael | Chief Officer | Profile | |
| Aaron Thome | Head Platform | Profile | |
| Michelle Frazier | Senior Affairs | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coya Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coya Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.